|
|
||||||||
J Thorac Cardiovasc Surg 2008;135:1372-1379
© 2008 The American Association for Thoracic Surgery
Cardiothoracic Transplantation |
a Department of Surgery, Division of Cardiothoracic Surgery, College of Physicians and Surgeons of Columbia University, New York, NY
b Department of Medicine, Division of Cardiology, College of Physicians and Surgeons of Columbia University, New York, NY
Received for publication April 25, 2007; revisions received November 7, 2007; accepted for publication November 13, 2007. * Address for reprints: Isaac George, MD, Department of Surgery, 630 W 168th St, P&S Building, Rm 17-415, New York, NY 10032. (Email: isaacgeorge{at}hotmail.com).
Objective: Biomaterials and textured surfaces in early pulsatile left ventricular assist devices (HeartMate I; Thoratec Corporation, Pleasanton, Calif) may increase immunologic risk through allosensitization. We hypothesized that axial-flow devices without biologic membranes or textured surfaces (HeartMate II; Thoratec; and DeBakey; MicroMed Cardiovascular, Inc, Houston, Tex) would cause less allosensitization than devices with such membranes and surfaces.
Methods: HeartMate II and DeBakey (n = 24) and HeartMate I (n = 36) devices were implanted from 1999 to 2006 in patients with severe heart failure cohort-matched for age, etiology, and support duration. Serum samples reacting with more than 10% of the HLA reference panel were considered positive for anti-HLA antibodies. Endomyocardial biopsy samples were collected after transplant.
Results: There were no significant cohort differences in age, etiology, sex, blood transfusion, or support duration. Anti-HLA antibodies were not detected at implantation of either HeartMate II and DeBakey or HeartMate I devices; however, significant increases in anti-HLA antibodies were present within 1 and 3 months of support with HeartMate I but not HeartMate II and DeBakey devices. Overall, fewer patients with HeartMate II and DeBakey devices demonstrated positive anti-HLA antibodies during support (8% vs 28%, P = .02), and fewer episodes of acute rejection per patient were seen within the first 9 posttransplant months(0.31 vs 0.69, P = .052). Long-term posttransplant survival was not different between groups.
Conclusion: Hemodynamic support with HeartMate II and DeBakey devices produced less allosensitization than did HeartMate I devices. Device selection may improve clinical outcomes for high-risk patients.
This article has been cited by other articles:
![]() |
A. H. Healy, N. O. Mason, M. E. Hammond, B. B. Reid, S. E. Clayson, S. G. Drakos, A. G. Kfoury, A. N. Patel, D. A. Bull, D. Budge, et al. Allograft Rejection in Patients Supported With Continuous-Flow Left Ventricular Assist Devices Ann. Thorac. Surg., November 1, 2011; 92(5): 1601 - 1607. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Arnaoutakis, T. J. George, A. Kilic, E. S. Weiss, S. D. Russell, J. V. Conte, and A. S. Shah Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: Update in a modern cohort J. Thorac. Cardiovasc. Surg., November 1, 2011; 142(5): 1236 - 1245.e1. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Bhamidipati, G. Ailawadi, J. Bergin, and J. A. Kern Early thrombus in a HeartMate II left ventricular assist device: A potential cause of hemolysis and diagnostic dilemma J. Thorac. Cardiovasc. Surg., July 1, 2010; 140(1): e7 - e8. [Full Text] [PDF] |
||||
![]() |
D. A. Bull, B. B. Reid, C. H. Selzman, R. Mesley, S. Drakos, S. Clayson, G. Stoddard, E. Gilbert, J. Stehlik, F. Bader, et al. The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation J. Thorac. Cardiovasc. Surg., July 1, 2010; 140(1): 169 - 173. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |